BRA
CCXI

Blue Rock Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History

Blue Rock Advisors’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-53,784
Closed -$2.95M – 105
2020
Q3 		$2.95M Buy
+53,784
New +$2.9M 2.54% 7

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Blue Rock Advisors's CCXI Position: Q4 2020 in Review

Blue Rock Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q4 2020, closing a stake of 53,784 shares — an estimated $2.95M sold.

Blue Rock Advisors first reported a position in CCXI in Q3 2020 and held it in 1 quarter. The position peaked at $2.95M in Q3 2020. 196 funds tracked by Wall St. Rank hold CCXI as of Q4 2020.

  • Blue Rock Advisors reported no remaining ChemoCentryx, Inc. position as of Q4 2020 after selling out during the quarter.
  • Blue Rock Advisors sold 53,784 ChemoCentryx, Inc. shares in Q4 2020, an estimated $2.95M.
  • Blue Rock Advisors first reported a position in ChemoCentryx, Inc. in Q3 2020 and held it in 1 quarter.
  • Blue Rock Advisors's ChemoCentryx, Inc. position peaked at $2.95M in Q3 2020.
  • 196 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2020.

Based on Blue Rock Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.